Tag: Phase Genomics

Phase Genomics has filed a notice of an exempt offering of securities to raise $6,579,358.00 in New Equity and Debt Financing.

Phase Genomics has filed a notice of an exempt offering of securities to raise $6,579,358.00 in New Equity and Debt Financing.

According to filings with the U.S. Securities and Exchange Commission, Phase Genomics is raising $6,579,358.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Ivan Liachko played a key role…

Read More Read More